Mahoney Michael F 4

What Happened Michael F. Mahoney, Chairman, President & CEO of Boston Scientific (BSX), exercised/converted derivative awards and received new equity awards. The filing shows conversion/exercise of 13,704 derivative shares (reported at $0.00), and two grants of restricted stock units (RSUs) of 55,652 and 131,329 shares (both $0.00). To satisfy tax withholding obligations related to these transactions, 6,626 shares were disposed at $74.12 each, generating $491,119 in proceeds. All acquisition entries are recorded at $0.00 because they are derivative awards/RSUs rather than open-market purchases.

Key Details

• Transaction date(s): February 12, 2026; Form filed February 17, 2026 (appears to be later than the usual 2-business-day Form 4 deadline).
• Exercise/conversion: 13,704 derivative shares acquired (reported at $0.00).
• Tax withholding/disposal: 6,626 shares sold/withheld at $74.12 = $491,119.
• Grants: 55,652 RSUs and 131,329 RSUs granted (both reported at $0.00).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnotes (high level):
  • F1: Each RSU = commitment to issue one share of common stock.
  • F2: 55,652 RSUs vest in four equal annual installments beginning Feb 12, 2025.
  • F3: 131,329 RSUs vest in four equal annual installments beginning Feb 12, 2027.
  • F4: Option grant (number not specified in excerpt) vests in four equal annual installments beginning Feb 12, 2027.
• Transaction codes: M = exercise/conversion of derivative; F = shares surrendered/withheld to cover taxes; A = grant/award.

Context

• This appears to be a routine equity compensation event: award/grant + exercise/conversion, with a portion of shares surrendered or sold to cover tax withholding (a common practice, effectively a cashless/net settlement). The reported disposal of 6,626 shares to cover taxes is not an open-market sale intended as a directional bet on the stock.
• Grants and RSUs are subject to vesting schedules (see footnotes), so most of the awarded shares are not immediately tradable. The filing date (Feb 17) vs. transaction date (Feb 12) suggests the Form 4 was filed after the standard two-business-day window; retail investors may note the late filing but should not infer intent from timing alone.

If you want, I can pull the exact “shares owned following the reported transaction” from the full Form 4 filing or show how these entries appear in the official SEC filing.